A second-generation SINE, orally bioavailable Exportin 1 (XPO1,CRM1) inhibitor with markedly reduced brain penetration compared to selinexor (30-fold less).

A second generation, orally biovailable pan-genotypic HCV NS5B polymerase inhibitor with EC50 of 1-10 nM.

A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.

A rodenticide that poisons the central nervous system by uncoupling mitochondrial oxidative phosphorylation, which causes a decrease in adenosine triphosphate (ATP) synthesis..

A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

A resorcylic lactone type covalent kinase inhibitor that inhibits ALK1 with IC50 of 125 nM, also inhibits FLT3, VEGFR2, VEGFR3, MEK2 with IC50 of 1-10 nM..

A receptor adenine derivative binding membrane brain animal cell line.For the detailed information of 9-methyladenine, the solubility of 9-methyladenine in water, the solubility of 9-methyladenine in DMSO, the solubility of 9-methyladenine in PBS buffer, the animal experiment (test) of 9-methyladenine, the cell expriment (test) of 9-methyladenine, the in vivo, in vitro and clinical trial test of 9-methyladenine, the EC50, IC50,and Affinity of 9-methyladenine, Please contact DC Chemicals..

A RARβ-selective agonist that exhibits a full transcriptional agonistic activity and activating RARβ as efficiently as the reference agonist TTNPB.

A RARβ/γ agonist originated from TTNPB, is also a selective inhibitor of aldo-keto reductase family member 1B10 (AKR1B10) with IC50 of 6.1 uM.

A radioligand candidate for arginine vasopressin 1B (V1B) receptor that exhibits high binding affinities for human and rat V1B receptors with IC50 of 0.526 and 0.641 nM, respectively.

A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM.

A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine.

A purine scaffold casein kinase 1δ/1ε (CK1δ/ε) inhibitor with IC50 of 160/540 nM, respectively..

A pungent agent isolated from Zingiber officinale Roscoe, has been known to have anti-tumor and anti-inflammatory effects.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that inhibits gastric acid secretion.

A PP1 analog that has greater selectivity and potency for Zap-70(AS) over wild-type Zap-70, as assessed by Erk and Lat phosphorylation, as well as by proliferative responses of mature CD4+ cells.

A potential antipsychotic agent that binds selectively to D4 and 5-HT2A receptors with Ki of 3.0 and 5.8 nM, respectively.

A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM.

A potent, subtype-selective mGluR5 negative allosteric modulator with Ki of 6.1 nM.

A potent, subtype-selective Grp94 inhibitor with Kd of 0.96 uM, 13-fold selectivity over Hsp90α.

A potent, state-dependent blocker of Cav2 channels that preferentially inhibits potassium-triggered calcium influx through recombinant Cav2.2 under depolarized conditions with IC50 of 0.27 uM, compared with hyperpolarized conditions (IC50>20 uM).

A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively).

A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.

A potent, specific, orally bioactive small-molecule inhibitor of ubiquitin-conjugating enzyme UbcH5c with Kd of 283 nM.

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.